Introduction
Erythromycin is the mainstay of antibiotic therapy for pertussis as it decreases the transmission of infection and ameliorates symptoms, particularly in younger, more severely affected infants. 1 Many in vitro studies have investigated the potency of other antibiotics against Bordetella spp, in particular the newer macrolides, ampicillin, trimethoprim-sulphamethoxazole, the quinolones and third-generation cephalosporins. [2] [3] [4] [5] [6] [7] Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis is not routinely performed owing to the lack of standardization of laboratory methods, the slowly growing and fastidious nature of the organism and, until recently, its universal susceptibility to erythromycin. In 1995, the first erythromycin-resistant B. pertussis isolate (MIC Ͼ256 mg/L by Etest) was described in a 2 month-old infant with clinical failure of erythromycin therapy. 8 Alternative therapeutic agents are now sought for the treatment of resistant B. pertussis strains, should they become common, and for use in patients unable to tolerate conventional therapy. However, although in vitro susceptibility data are available for B. pertussis, in vivo efficacy data are lacking.
In clinical practice, alternative agents for the treatment of pertussis have to be selected on microbiological and pharmacokinetic criteria since clinical data are not available. The quinolones achieve high concentrations in respiratory secretions. 9 Gemifloxacin (SB-265805) is a novel quinolone. This study aimed to determine the in vitro activity of gemifloxacin and comparator agents against B. pertussis and Bordetella parapertussis.
Materials and methods

Bacterial strains
The following bacterial isolates were tested: 102 strains of 
MIC determination
The assay conditions used in this study were those proposed by Hoppe & Haug in 1988, 10 and further developed by Mortensen et al. 11 Briefly, the broth microdilution procedure was performed using Mueller-Hinton broth supplemented with 5% lysed horse blood. The inoculum used was a bacterial suspension equivalent to a final density of 5 ϫ 10 5 cfu/mL for all isolates, and was confirmed with plate counts. Streptococcus pneumoniae ATCC 49619 was used as the quality control strain since no B. pertussis quality control strain has been validated for susceptibility testing. Microtitre plates were incubated in ambient air for 48 h at 37°C, and the MIC was defined as the lowest concentration of antimicrobial compound at which growth was inhibited.
Results
The activities of the panel of antimicrobial agents against the test strains are presented in the Table. Erythromycin, azithromycin, ciprofloxacin and gemifloxacin were consistently active against both species. The single azithromycinand erythromycin-resistant B. pertussis strain tested was not cross-resistant to any of the other agents tested (gemifloxacin MIC, р0.008 mg/L; ciprofloxacin, р0.015 mg/L; ampicillin, 2.0 mg/L; trimethoprim-sulphamethoxazole, 4.0 mg/L).
Discussion
The in vitro activities of ampicillin, azithromycin, erythromycin, ciprofloxacin and trimethoprim-sulphamethoxazole recorded in this study against B. pertussis and B. parapertussis were comparable to those found in previous reports. 3, 4, 6, 7 In vitro data on the potency of gemifloxacin against B. pertussis and B. parapertussis have not previously been reported, but these findings are comparable to those of other quinolones which had MIC ranges of 0.03-0.5 mg/L for these pathogens. 2, 5, 6 Should gemifloxacin respiratory tract secretion concentrations prove to be similar to other quinolones, this, coupled with the in vitro potency of gemi- floxacin against B. pertussis and B. parapertussis, suggests that gemifloxacin could be a future therapeutic option in the treatment of pertussis, particularly in adults who serve as a reservoir for the disease in children. 12 Although quinolones are not yet approved for use in children, because of safety concerns, there is growing experience in their use in paediatric patients. 13, 14 Once quinolone safety data allow more widespread paediatric use, clinical trials will be needed to assess the clinical efficacy of quinolones in children with pertussis.
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